Tag Archives: Price-volume procurement

Hunan Implements National Coronary Stent VBP Second‑Round Continuation Results – Province‑Wide Execution From 1 October 2026 With Red/Yellow Price Guardrails

Regulatory Milestone

Item	Detail
Issuing Agency	Hunan Provincial Healthcare Security Administration
Document	Xiang Yi Bao Han [2026] No. 37 (issued 9 Sep 2026)
Policy Type	Provincial implementation of national VBP second‑round continuation selection results
Product Scope	Coronary stent consumables – selected products per the attached national list
Effective Date	1 October 2026 (province‑wide unified execution)
Procurement Cycle	Through 30 June 2029; first contract year covers 1 Oct 2026 – 31 Dec 2027; agreements signed annually
Key Deadlines	Supplier registration & distribution setup on the Hunan Medical Procurement Platform by 30 Sep 2026; tripartite purchase‑sale agreements signed by 1 Nov 2026

Procurement Mechanism & Compliance Requirements

Participating Institutions: All public medical institutions (including military facilities) and all institutions that reported volumes are required to purchase and use selected products; other medical‑insurance‑contracted institutions are encouraged to participate.
Agreed Volumes: Annual contracted volumes are the quantities confirmed by hospitals in the procurement system (communicated separately to hospitals and winning suppliers). The first‑year volume is scaled at 15/12 of the annual agreement (rounded), reflecting the 15‑month initial contract period; non‑integer results are rounded.
Beyond‑Agreement Supply: Purchases exceeding the agreed volume must still be supplied by winning companies at the selected price until the end of the procurement cycle.
Platform‑Only Trading: All transactions must run through the Hunan Medical Procurement Platform; offline procurement, secondary price negotiation and any form of discount are strictly prohibited.
Usage Floor: Selected products must account for no less than 80% of total same‑category procurement and usage volume during the agreement period; hospitals may buy other price‑appropriate products only after fulfilling contracted volumes.
No Hidden Fees: Hospitals (including third‑party service providers) may not charge any additional fees for market entry, inventory or clinical use of selected stents, and may not block access citing cost control, product‑count limits, unreported volumes, quality deposits or distributor account caps.
Supply Responsibility: Winning companies are the first‑line responsible party for quality and supply, and must maintain emergency stockpiles and report capacity shortfalls to the provincial bureau in advance; prior distribution relationships are automatically cleared upon implementation. Non‑compliance (supply failure, quality defects) will be escalated to the Joint Procurement Office, with penalties, disqualification and credit‑system consequences applied.

Price Guardrails – Red/Yellow Label Monitoring

Under the “price‑procurement linkage” mechanism, non‑selected coronary stents listed on the platform at elevated prices will carry warning labels benchmarked to the highest selected price, with procurement risk alerts issued to hospitals:

Product Category	Yellow Label Threshold (≥1.8× highest selected price)	Red Label Threshold (≥2.5× highest selected price)
Non‑selected coronary drug‑eluting alloy stents	¥1,708 / unit	¥2,372 / unit
Non‑selected coronary drug‑eluting stainless‑steel stents	¥1,526 / unit	¥2,120 / unit

Selected‑product awarded prices and company‑level results were not disclosed in the provincial notice (referenced to the national attachment list).

Market Impact & Outlook

Continuity Signal: The second‑round continuation locks the nationally pioneered coronary stent VBP framework in place through mid‑2029, extending price certainty for hospitals and winning manufacturers after the landmark first round that reset China’s stent market.
Pressure on Non‑Selected Products: The explicit red/yellow label price ceilings (1.8× / 2.5× the top awarded price) effectively cap how long premium‑priced non‑selected stents can compete in Hunan, pushing hospitals toward selected products and squeezing margin room for out‑of‑award brands.
Hospital Enforcement Teeth: Execution progress is subject to “monthly monitoring and annual evaluation,” and is written into medical‑insurance designated‑hospital agreement assessments; hospitals with serious lag, unfulfilled volumes or heavy use of high‑priced non‑selected products face contractual consequences.
Supplier Reset: Automatic clearing of prior distribution relationships forces winning companies to rebuild logistics coverage within weeks of the notice, while distributor performance (order response, delivery) becomes a compliance exposure for manufacturers.
National Alignment: The notice stipulates that any national policy adjustments during the cycle will be followed accordingly, keeping Hunan’s execution synchronized with the central healthcare security authority’s continuation‑procurement playbook.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding procurement execution timelines, contract volumes, supply arrangements and price‑monitoring enforcement for the coronary stent VBP continuation in Hunan Province. Actual outcomes may differ due to risks including national policy adjustments, supplier capacity and distribution readiness, hospital compliance dynamics, and quality or supply disruptions. Company‑level awarded prices and volumes are not disclosed in the provincial notice.-China Health Reform Pulse

Policy Source: http://ybj.hunan.gov.cn/ybj/first113541/firstF/f3113607/202609/t20260910_34061201.html

Yunnan Lists Coronary Stent Procurement Winners for Second Round

Leave a reply

Kunming, Sept 4, 2026 — Yunnan’s Government Procurement and Concession Center announced the online listing of selected products for the second round of national coronary stent volume-based procurement, launching a new procurement cycle running from Sept 15, 2026, to June 30, 2029, while terminating transaction eligibility for products under the previous agreement.

Policy Snapshot

Attribute	Detail
Issuers	Yunnan Government Procurement and Concession Center; Yunnan Provincial Medical Security Bureau
Document	Notice on the Work of Hanging Selected Products in the Second Round of National Coronary Stent Centralized Procurement
Platform	Yunnan Medical Insurance Information Platform — Drug and Medical Consumables Procurement Management Subsystem
Procurement cycle	Sept 15, 2026 – June 30, 2029
Agreement structure	Tripartite (one-year renewable contracts)
Key actions	Online listing of selected products; price governance for non-selected products

Key Provisions

Selected product listing — Winning products are listed on the procurement subsystem for transaction and settlement. Products listed under the previous agreement period are simultaneously delisted.
Distributor designation — Selected enterprises independently designate distribution partners through the procurement subsystem and establish delivery relationships. Annual tripartite agreements are signed to define rights and obligations.
Price governance — Non-selected products with excessively high listed prices are assigned “red/yellow” warning labels. Enterprises receiving targeted notifications must adjust prices accordingly; those without notifications are outside this round’s price governance scope.
Dynamic listing compliance — Non-selected products must follow the dynamic listing rules under Yunnan Medical Security Bureau [2022] No. 92 for application and price adjustment.
System registration — Enterprises without existing accounts must complete registration on the procurement subsystem per the March 20, 2024, platform notice.

Market Impact Analysis

The nearly three-year procurement cycle provides supply certainty for coronary stent manufacturers and cardiology departments across Yunnan’s public hospital network. By automatically terminating the previous agreement and activating the new second-round listings, regulators are ensuring a clean transition without overlapping transaction eligibility that could confuse hospital procurement officers.

The “red/yellow” warning system for non-selected products is a particularly consequential market-shaping tool. By flagging overpriced non-winners, the mechanism extends the price compression effect of national volume-based procurement beyond the selected supplier pool, pressuring the entire competitive set to align with national benchmarks or risk exclusion from hospital formularies. This creates a de facto price ceiling for the coronary stent market in Yunnan, compressing margins for both domestic and international manufacturers that failed to secure selected status.

For selected enterprises, the ability to independently designate distributors offers operational flexibility, though the annual tripartite agreement structure introduces yearly renegotiation leverage points for hospitals. The requirement for enterprises without platform accounts to register before participating ensures full traceability in the procurement chain but may delay market entry for smaller manufacturers unfamiliar with Yunnan’s digital procurement infrastructure.

Forward-Looking Statement

Industry analysts expect the Sept 15 launch to serve as a template for other provincial procurement centers rolling out the national coronary stent second-round agreement in the coming weeks. The three-year cycle ending in mid-2029 gives manufacturers long-term volume visibility, though the annual distributor agreement renewals create recurring compliance checkpoints. The red/yellow price warning system is likely to be replicated across other high-value device categories—such as orthopedic implants and pacemakers—as provincial regulators seek to manage non-selected product pricing without resorting to formal delisting. Companies with coronary stent portfolios should monitor Yunnan’s platform closely, as the dynamic listing rules for non-selected products may trigger additional price adjustment mandates before year-end.-China Health Reform Pulse

Policy Source: http://www.ynyyzb.com.cn/detail.html?infoId=27794&CatalogId=3

China Approves 13th Batch of National Drug Procurement Information Changes

Leave a reply

Beijing, Sept 4, 2026 — China’s National Drug Centralized Procurement Office approved the 13th batch of information changes for selected drugs under the national volume-based procurement program, allowing winning manufacturers to update marketing authorization holders, production sites, specifications, packaging, and corporate names without losing their selected status.

Policy Snapshot

Attribute	Detail
Issuer	National Drug Centralized Procurement Joint Office
Document	Notice on Information Changes of Selected Drugs in National Centralized Procurement (13th Batch)
Effective date	Sept 4, 2026
Scope	Selected drugs under national volume-based procurement
Permitted changes	Marketing authorization holder; manufacturer; specifications; packaging; corporate name
Condition	Selected enterprises must meet specified eligibility criteria
Action required	Information linkage updates; platform listing adjustments; procurement coordination

Key Provisions

Under the National Drug Centralized Procurement Document and related regulations, winning enterprises that satisfy defined conditions may modify critical product and corporate information while retaining their selected procurement qualification. The office verified enterprise application materials before granting approval for the 13th batch of changes. All relevant parties—including medical institutions, distributors, and procurement platforms—must promptly complete information synchronization, online listing updates, and purchasing workflow adjustments to reflect the revised drug details.

Market Impact Analysis

The 13th batch approval signals continued regulatory flexibility within China’s rigid national procurement framework, acknowledging that corporate restructuring, manufacturing consolidation, and product line optimization are inevitable in a market undergoing rapid consolidation. By allowing marketing authorization holder and production site transfers without stripping selected status, regulators are preventing supply disruptions that could arise if every corporate change triggered automatic re-tendering.

For pharmaceutical companies, the change mechanism provides a critical pathway to optimize manufacturing footprints and transfer assets between subsidiaries without sacrificing the hard-won volume commitments secured through national bidding. However, the requirement to meet unspecified “certain conditions” implies that not all change requests are automatically approved, creating a compliance gate that favors well-resourced enterprises capable of navigating administrative verification.

For hospitals and procurement platforms, the batch release demands immediate system updates to ensure that purchasing records, invoice matching, and inventory management align with the revised drug information. Failure to synchronize could result in settlement delays or compliance flags during audits.

Forward-Looking Statement

Industry analysts expect the national procurement office to maintain a regular cadence of information change approvals—likely quarterly or monthly—as the volume-based procurement program matures and corporate restructuring accelerates across the domestic pharmaceutical sector. The 13th batch suggests the approval pipeline is processing applications efficiently, with minimal backlog. Companies planning mergers, acquisitions, or manufacturing transfers for selected products should file change applications proactively, as the office’s willingness to approve such modifications reduces the regulatory risk traditionally associated with post-award corporate actions. The batch release also sets a template for provincial procurement alliances, many of which are expected to adopt similar change-management protocols to ensure supply continuity across decentralized procurement networks.-China Health Reform Pulse

Policy Source: https://www.smpaa.cn/gjsdcg/2026/09/04/24314.shtml